Vaprisol

AssetAlso called conivaptan, YM-087, CI-1025

Blocks vasopressin V1A and V2 receptors, promoting free-water excretion and reducing vasopressin-mediated vasoconstriction.

Stage
Approved
Modality
Small molecule
Target
AVPR1A
9
Indications
15
Trials
1
Developer

Approved by the FDA on Dec 29, 2005 (NDA021697). 2 approvals stand. FDA

Indications

9

6 more

In the full profile

  • Target and mechanism3
  • Owner and partners1
  • Trials15
  • Evidence for its targets2
  • Competitors12
  • Signals10

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets